ReviewEye and brain2018
Profile of tocilizumab and its potential in the treatment of giant cell arteritis.
Review in Eye and brain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- European Headache Federation recommendations for neurologists managing giant cell arteritis.The journal of headache and pain · 2020Pooled it
- Giant cell arteritis: reviewing the advancing diagnostics and management.Eye (London, England) · 2023Review
- An update on the clinical approach to giant cell arteritis.Clinical medicine (London, England) · 2022Article
- Role of temporal artery resection in Horton's arteritis (Review).Experimental and therapeutic medicine · 2021Review
- Monckeberg's Medial Sclerosis as a Cause for Headache and Facial Pain.Current pain and headache reports · 2021Review
- A new era for giant cell arteritis.Eye (London, England) · 2020Review
- Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis.Ophthalmology and therapy · 2019Review
- Vasculitis: A Checklist to Approach and Treatment Update for Dermatologists.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this group of patients, and conventional steroid-sparing therapies have not yet shown enough of a clinical benefit to change the standard of care. As the understanding of the underlying immunopathophysiology of GCA has increased, positive clinical observations have been made with the use of IL-6 receptor inhibitor therapies, such as tocilizumab (TCZ). This has led to prospective randomized control trials that have highlighted the safety and efficacy of TCZ in both new-onset and relapsing GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.